Thirty-two human proteome microarrays were used to profile serum samples from 16 healthy volunteers and 16 renal cancer patients (Table 1), and the workflow is illustrated inFigure 1A. Anti-human antibodies showing different fluorescence types were adopted to mark IgG or IgM in serum, which could bind to the recombinant proteins of the microarray. The gene discussed is CD40LG; the disease is renal carcinoma.